Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy

Cancer

Volumn 82, Issue 6, 1998, Pages 1049-1055

  Fizazi, Karim ^a   Cojean, Isabelle ^a   Pignon, Jean Pierre ^a   Rixe, Olivier ^a   Gatineau, Michel ^a   Hadef, Souad ^a   Arriagada, Rodrigo ^a   Baldeyrou, Pierre ^a   Comoy, Etienne ^a   Le Chevalier, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Neuron specific enolase; Prognostic factors; Small cell lung carcinoma Tumor markers

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032521505     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1049::AID-CNCR6>3.0.CO;2-9     Document Type: Article

References (45)

1. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215-20.
2. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985;45:2878-82.
3. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46:4189-94.
4. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344-54.
5. Albain K, Crowley J, Livingston R. Prognostic factors in limited small cell (LSC) lung cancer reconsidered: Southwest Oncology Group (SWOG) studies. Proc Am Soc Clin Oncol 1989;8:225.
6. Gronowitz JS, Bergström R, Nôu E, Pahlman S, Brodin O, Nilsson S, et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer: a multivariate analysis. Cancer 1990;66:722-32.
7. Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. Br J Cancer 1990;61:597-604.
8. Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, et al. Small cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 1991;9:1639-49.
9. Jorgensen LGM, Osterlind K, Genollé J, Gomm SA, Hernandéz JR, Johnson PWN, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariate analysis on data from nine centres. Br J Cancer 1996;74:463-7.
10. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991;63:986-92.
11. Arriagada R, Kramar A, Le Chevalier T, De Cremoux H. Competing events determining relapse-free survival in limited small-cell lung carcinoma: the French Cancer Centers' Lung Group. J Clin Oncol 1992;10:447-51.
12. Arriagada R, Le Chevalier T, Pignon JP, Rivière A, Monnet I, Chomy P, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-52.
13. Carney DN, Marangas PJ, Ihde DC, Bunn PJ, Cohen MN, Minna JD. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982;1:583-5.
14. Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, et al. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 1990;65:1386-90.
15. Splinter TAW, Cooper EH, Kho GS, Oosterom R, Peake MD. Neuron specific enolase as a guide to the treatment of small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:171-6.
16. Gomm SA, Keevil BG, Thatcher N, Hastleton PS, Swindell RS. The value of tumour markers in lung cancer. Br J Cancer 1988;58:797-804.
17. Jorgensen LGM, Osterlind K, Hansen HH, Cooper EH. Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). Br J Cancer 1992;66:594-8.
18. Quoix E, Charloux A, Popin E, Pauli G. Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer. Eur J Cancer 1993;29A:2248-50.
19. Johnson PWM, Joel SP, Love S, Butcher M, Pandian MR, Squires L, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993;67:760-6.
20. Milleron B, Cadranel J, Liote H, François T, Scarna H, Akoun G. Prognostic value of serum neuron-specific enolase (SNSE) in small-cell lung cancer (SCLC). Lung Cancer 1988;4(Suppl):A47.
21. Jorgensen LGM, Osterlind K, Hansen HH, Cooper EH. The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer 1988;58:805-7.
22. Harding M, Mc Allister J, Hulks G, Vernon D, Monie R, Paul J, et al. Neuron specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer 1990;61:605-7.
23. Van Der Gaast A, Van Putten WLJ, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TA. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer 1991;64:369-72.
24. World Health Organization. Histological typing of lung tumors. 2nd edition. Geneva: World Health Organization, 1981.
25. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication No. 48. Geneva: World Health Organization, 1979.
26. De Vathaire F, Arriagada R, de Thé H, Tarayre M, Ruffié P, Chomy P, et al. Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung carcinoma. Lung Cancer 1993;8:301-8.
27. Le Chevalier T, Thomas F, Subirana R, Baldeyrou P, Ruffié P, Arriagada R, et al. A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma. Cancer 1991;67:2980-3.
28. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analyses of randomized clinical trials requiring prolonged observation of each patient. II. Analyses and examples. Br J Cancer 1977;35:1-39.
29. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187.
30. Armitage P. Statistical methods in medical research. Oxford: Blackwell, 1971.
31. Breslow N, Day N. Statistical methods for the analysis of case control studies. Lyon: International Agency for Research on Cancer, 1980.
32. Nõu E, Steinholtz L, Bergh J, Nilsson K, Pahlman S. Neuron-specific enolase as a follow-up marker in small-cell bronchial carcinoma. Cancer 1990;65:1380-5.
33. Fishhach W, Schwarz-Wallrauch C, Jany B. Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 1989;63:1143-9.
34. Jacques G, Bepler G, Holle R, Wolf M, Hannich T, Gropp C, et al. Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer 1988;62:125-34.
35. Jorgensen LG, Osterlind K, Hansen HH, Cooper EH. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). Br J Cancer 1994;70:759-61.
36. Akoun GM, Scarna HM, Milleron BJ, Bénichou MP, Herman DP. Serum neuron specific enolase: a marker for disease extent and response to therapy for small cell lung cancer. Chest 1985;1:39-43.
37. Spinazzi A, Soresi E, Boffi R, Nonis A, Noseda A, Cobelli S, et al. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer. Cancer Detect Prev 1994;18:209-20.
38. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
39. Coldman AJ, Coppin CML, Goldie JH. Models for dose intensity. Math Biosci 1988;92:97-113.
40. Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990;50:5904-10.
41. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
42. Fisken J, Leonard RCF, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, et al. The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993; 68:140-5.
43. Sculier JP, Feld R, Evans WK, Shepherd FA, De Boer G, Malkin DG, et al. Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol 1985;3:1349-54.
44. Laberge F, Fritsche HA, Umsawasdi T, Carr DT, Welch S, Murphy WK, et al. Use of carcinoembryonic antigen in small cell lung cancer: prognostic value and relation to the clinical course 1. Cancer 1987;59:2047-52.
45. Maestu I, Pastor M, Gómez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer, a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8:547-53.